Aktis Oncology, Inc.

Healthcare · Biotechnology

18.50$ +0.0% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Balance Sheet

Aktis Oncology, Inc. (AKTS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 558 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet AKTS
Line item	Q4 15	Q1 16	Q2 16	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q3 24	Q4 24	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	2.9	3.1	4.5	3.6	5.9	11	18	17	25	20	29	25	58	52	48	42	69	63	71	64	78	125	125	121	134	161	–	145	132	158	149	127	112	103	337	326	279	265	577	558
Current Assets	2.6	2.8	4.3	3.2	5.2	10	10	6.1	12	7.3	16	11	43	36	32	24	48	41	46	39	51	95	93	83	75	92	–	73	60	68	60	39	26	29	315	301	249	230	544	525
Cash	2.5	2.7	4.2	3.1	5.0	9.4	9.6	5.4	12	6.5	15	9.1	42	35	30	23	46	40	44	37	48	90	88	76	67	80	–	61	47	53	43	26	13	15	225	37	180	38	372	82
Cash & Short-Term Investments	2.5	2.7	4.2	3.1	5.0	9.4	9.6	5.4	12	6.5	15	9.1	42	35	30	23	46	40	44	37	48	90	88	76	67	80	–	61	47	53	43	26	13	15	312	297	246	227	538	517
Receivables	–	–	–	–	0.0	–	–	0.3	0.3	0.5	0.2	0.3	0.3	0.2	0.3	0.6	1.1	0.7	0.4	0.3	0.7	1.6	1.2	1.4	2.5	3.8	–	3.0	3.2	4.2	4.8	3.9	6.1	5.6	7.0	–	–	–	2.2	2.3
Inventory	–	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.7	1.4	1.4	2.1	2.3	4.1	–	4.5	5.8	7.6	7.5	6.2	5.5	5.1	3.2	–	–	–	–	–
Goodwill	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	7.8	8.1	–	8.1	8.1	15	15	15	15	6.5	6.5	–	–	–	–	–
Intangible Assets	0.0	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.4	0.4	0.4	0.5	0.5	0.5	0.6	0.6	0.6	0.6	0.6	10	9.0	–	8.6	8.3	16	15	15	14	13	12	–	–	–	–	–
Total Liabilities	0.7	0.7	1.9	2.3	1.3	1.3	3.1	5.6	4.9	3.2	15	15	21	22	22	23	25	24	30	29	31	7.5	7.6	8.1	10	58	–	58	53	57	63	59	58	61	414	414	411	411	71	73
Current Liabilities	0.5	0.4	0.5	0.8	0.9	1.3	1.4	3.8	3.1	2.0	2.6	2.2	2.6	2.8	3.2	2.7	4.1	3.6	6.1	4.2	15	6.8	7.3	7.9	7.1	13	–	13	8.8	12	18	16	14	18	17	19	27	31	28	32
Short-Term Debt	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.2	0.2	0.4	0.5	0.5	11	1.7	0.5	0.6	0.6	0.3	–	0.6	0.5	0.8	0.9	0.9	1.0	2.2	1.5	1.3	1.4	1.3	1.4	1.5
Accounts Payable	–	0.0	0.1	0.1	0.0	0.1	0.5	1.6	1.1	0.1	0.1	0.4	0.8	0.3	0.2	0.2	1.5	0.6	2.1	0.7	0.9	0.9	1.2	3.6	1.8	3.6	–	4.2	2.6	3.1	4.0	6.0	3.2	4.8	0.7	1.9	2.4	1.7	1.2	2.5
Shareholders' Equity	2.2	2.4	2.7	1.3	4.6	9.8	15	11	20	17	14	9.1	37	30	26	19	44	38	41	35	46	118	117	112	116	103	–	87	79	100	86	68	54	42	-77	-88	-132	-146	506	485
Retained Earnings	-3.4	-4.2	-6.7	-8.7	-12	-14	-16	-21	-27	-31	-38	-46	-52	-62	-67	-76	-86	-94	-104	-116	-127	-138	-148	-161	-176	-207	–	-226	-237	-253	-270	-291	-306	-330	-81	-93	-141	-157	-175	-199
Shares Outstanding	13	15	15	16	16	18	19	19	20	22	22	22	28	30	30	30	31	36	38	38	39	46	51	51	53	55	54	57	58	68	72	72	73	91	154	53	53	53	55	55

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings